Osteopontin as a factor of neuroinflammation in chronic non-infectious diseases
- Authors: Matveeva M.V.1, Samoilova Y.G.1, Kudlay D.A.2,3, Ratkina K.R.1, Podchinenova D.V.1, Oleinyk O.A.1, Diraeva N.M.1
-
Affiliations:
- Siberian State Medical University
- NRC Institute of Immunology FMBA of Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 19, No 3 (2021)
- Pages: 27-31
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2918/article/view/113415
- DOI: https://doi.org/10.29296/24999490-2021-03-04
- ID: 113415
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
Maria Vladimirovna Matveeva
Siberian State Medical University
Email: mariia@yandex.ru
Associate Professor, Department of Children's Diseases, Department General Medical Practice and outpatient Therapy
Yulia Gennadievna Samoilova
Siberian State Medical University
Email: samoilova_y@inbox.ru
Head of the Department of Childhood Illnesses, Professor, of Department of Faculty Therapy with Clinical Pharmacology
Dmitry Anatolievich Kudlay
NRC Institute of Immunology FMBA of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: d624254@gmail.com
leading researcher of the laboratory of personalized medicine and molecular immunology №71; professor of the Department of Pharmacology of the Institute of Pharmacy
Ksenia Rashitovna Ratkina
Siberian State Medical University
Email: kseniahakimova@gmail.com
resident of the Department of Psychiatry, Narcology and Psychotherapy
Darya Vasilyevna Podchinenova
Siberian State Medical University
Email: darvas_42@mail.ru
Assistant of the Department of Children's Diseases
Oksana Alekseevna Oleinyk
Siberian State Medical University
Email: oleynikoa@mail.ru
Associate Professor, Department of Faculty Therapy with a Course of Clinical Pharmacology
Nargiz Muguma Diraeva
Siberian State Medical University
Email: ndiraeva94@mail.ru
qizi - Postgraduate student of Children's Diseases Department
References
- Kahles F., Findeisen H.M., Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014; 3 (4): 384-93. doi: 10.1016/j.molmet.2014.03.004
- Sarosiek K., Jones E., Chipitsyna G., Al-Zoubi M., Kang C., Saxena S., Gandhi A.V., Sendiky J., Yeo C.J., Arafat H.A. Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN. J. Gastrointest Surg. 2015; 19 (4): 639-50. DOI: 10.1007/ s11605-014-2735-6.
- Icer M.A., Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018; 59: 17-24. doi: 10.1016/j.clinbiochem.2018.07.003.
- Ahlqvist E., Osmark P., Kuulasmaa T., Pilgaard K., Omar B., Brons C. Link between GIP and osteopontin in adipose tissue and insulin resistance. Diabetes. 2013; 62: 2088-94.
- Kiefer F.W., Zeyda M., Todoric J., Huber J., Geyeregger R., Weichhart T. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008; 149: 1350-7.
- Nomiyama T., Perez-Tilve D., Ogawa D., Gizard F., Zhao Y, Heywood E.B. Osteo-pontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J. of Clinical Investigation. 2007; 117: 2877-88.
- Kiefer F.W., Zeyda M., Gollinger K., Pfau B., Neuhofer A., Weichhart T. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes. 2010; 59: 935-46.
- Chapman J., Miles P.D., Ofrecio J.M., Neels J.G., Yu J.G., Resnik J.L. Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS One. 2010; 5: e13959.
- Samuvel D.J., Sundararaj K.P., Li Y, Lopes-Virella M.F., Huang Y. Adipocyte-mononu-clear cell interaction, toll-like receptor 4 activation, and high glucose synergistically up-regulate osteopontin expression via an interleukin 6-mediated mechanism. J. of Biological Chemistry. 2010; 285: 3916-27.
- Omar B., Banke E., Guirguis E., Akesson L., Manganiello V., Lyssenko V. Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes - a role for the transcription factor NFAT and phosphodiesterase 3B. Biochemical and Biophysical Research Communications. 2012; 425: 812-7.
- Gualillo O., Gonzalez-Juanatey J.R., Lago F The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends in Cardiovascular Medicine. 2007; 17: 275-83.
- Schinzari F, Tesauro M., Bertoli A., Valentini A., Veneziani A., Campia U., Cardillo C. Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents. Am J Physiol Endocrinol Metab. 2019; 317 (4): 658-66. doi: 10.1152/ajpendo.00204.2019.
- Komorowski J., Jankiewicz-Wika J., Kolomecki K., Cywinski J., Piestrzeniewicz K., Swietoslawski J. Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine. 2011; 55: 56-61.
- Schaller G., Aso Y., Schernthaner G.H., Kopp H.P., Inukai T., Kriwanek S. Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obesity Surgery. 2009; 19: 351-6.
- Zeyda M., Gollinger K., Todoric J., Kiefer F.W., Keck M., Aszmann O. Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. Endocrinology. 2011; 152: 2219-27.
- Karamizadeh Z., Kamali Sarvestani E., Saki F, Karamifar H., Amirhakimi G.H., Namavar Shooshtarian M.H., Ashkani-Esfahani S. Investigation of osteopontin levels and genomic variation of osteopontin and its receptors in Type 1 diabetes mellitus. J. Endocrinol Invest. 2013; 36 (11): 1090-3. doi: 10.3275/9098.
- Talat M.A., Sherief L.M., El-Saadany H.F, Rass A.A., Saleh R.M., Sakr M.M. The Role of Osteopontin in the Pathogenesis and Complications of Type 1 Diabetes Mellitus in Children. J. Clin. Res Pediatr Endocrinol. 2016; 8 (4): 399-404. DOI: 10.4274/ jcrpe.3082.
- El Dayem SMA, El Bohy AEM, Battah AA, Hamed M, El Aziz SHA. Osteopontin for Early Detection of Microvascular and Macrovascular Type 1 Diabetic Complication. Open Access Maced J. Med Sci. 2019; 7 (21): 3619-22. doi: 10.3889/oam-jms.2019.613.
- Icer M.A., Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018; 59: 17-24. doi: 10.1016/j.clinbiochem.2018.07.003
- Maser R.E., Lenhard M.J., Pohlig R.T., Balagopal P.B. Osteopontin and osteoprotegerin levels in type 2 diabetes and their association with cardiovascular autonomic function. J. Diabetes Complications. 2016; 30 (3): 507-10. doi: 10.1016/j.jdiaco-mp.2015.12.012.
- Gao N., Zhang-Brotzge X., Wali B., Sayeed I., Chern J.J., Blackwell L.S., Kuan C.Y., Reisner A. Plasma osteopontin may predict neuroinflammation and the severity of pediatric traumatic brain injury. J. Cereb Blood Flow Metab. 2020; 40 (1): 35-43. doi: 10.1177/0271678X19836412.
- Maser R.E., James Lenhard M., Pohlig R.T., Babu Balagopal P. Osteopontin and clusterin levels in type 2 diabetes mellitus: differential association with peripheral autonomic nerve function. Neurol Sci. 2017; 38 (9): 1645-50. doi: 10.1007/s10072-017-3019-1.
- Sponder M., Fritzer-Szekeres M., Marculescu R., Litschauer B., Strametz-Juranek J. Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease. Heart Vessels. 2016; 31 (10): 1603-8. doi: 10.1007/s00380-015-0778-6.
- Abdalrhim A.D., Marroush T.S., Austin E.E., Gersh B.J., Solak N., Rizvi S.A., Bailey K.R., Kullo I.J. Plasma Osteopontin Levels and Adverse Cardiovascular Outcomes in the PEACE Trial. PLoS One. 2016; 11 (6): e0156965. doi: 10.1371/journal.pone.0156965.
- Podzimkova J., Palecek T., Kuchynka P., Marek J., Danek B.A., Jachymova M., Kalousova M. Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy Herz. 2019; 44 (4): 347-353. doi: 10.1007/s00059-017-4645-3.
- Yang Y., Wang Y., Gao P.J. Osteopontin associated with left ventricular hypertrophy and diastolic dysfunction in essential hypertension. J. Hum Hypertens. 2020; 34 (5): 388-96. doi: 10.1038/s41371-019-0246-3.
- Lin R., Wu S., Zhu D., Qin M., Liu X. Osteo-pontin induces atrial fibrosis by activating Akt/GSK-3β/β-catenin pathway and suppressing autophagy. Life Sci. 2020; 245: 117328. doi: 10.1016/j.lfs.2020.117328
- El-Din D.S.S., Amin A.I., Egiza A.O. Utility of Tissue Inhibitor Metalloproteinase-1 and Osteopontin as Prospective Biomarkers of Early Cardiovascular Complications in Type 2 Diabetes. Open Access Maced J. Med Sci. 2018; 6 (2): 314-9. doi: 10.3889/oam-jms.2018.081
- Hao C., Cui Y., Owen S., Li W., Cheng S., Jiang W.G. Human osteopontin: Potential clinical applications in cancer (Review). Int J. Mol Med. 2017; 39 (6): 1327-37. doi: 10.3892/ijmm.2017.2964
- Yu A., Guo K., Qin Q., Xing C., Zu X. Clinico-pathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis. Biosci Rep. 2021: BSR20203531. doi: 10.1042/BSR20203531.
- Sun T., Li P., Sun D., Bu Q., Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97 (43): e12954. DOI: 10.1097/ MD.0000000000012954.
- Gu X., Gao X.S., Ma M., Qin S., Qi X., Li X., Sun S., Yu H., Wang W., Zhou D. Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis. Oncotarget. 2016; 7 (43): 69666-73. doi: 10.18632/oncotarget.11936.
- Lan Z., Fu D., Yu X., Xi M. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Fam Cancer. 2016; 15 (2): 221-30. DOI: 10.1007/ s10689-015-9847-3. PMID: 26458935.
- Pizzamiglio C, Ripellino P, Prandi P, Clemente N, Saggia C, Rossi V, Strigaro G. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiol Clin. 2020;50(1):47-54. doi: 10.1016/j.neu-cli.2019.12.001.
- Chung A.G., Frye J.B., Zbesko J.C., Constantopoulos E., Hayes M., Figueroa A.G., Becktel D.A. Liquefaction of the Brain following Stroke Shares a Similar Molecular and Morphological Profile with Atherosclerosis and Mediates Secondary Neurodegeneration in an Osteopontin-Dependent Mechanism. eNeuro. 2018; 5 (5): ENEURO.0076-18.2018. DOI: 10.1523/ ENEURO.0076-18.2018.
- Chimparlee N., Chuaypen N., Khlaiphuengsin A., Pinjaroen N., Payungporn S. Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis B-related hepatocellular carcinoma. Asian Pac J. Cancer Prev. 2015; 16: 7211-7. doi: 10.7314/AP-JCP.2015.16.16.7211
- Poruk K.E., Firpo M.A., Scaife C.L., Adler D.G., Emerson L.L., Boucher K.M., Mulvihill S.J. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas. 2013; 42: 193-7 doi: 10.1097/MPA.0b013e31825e354d
- Carbone F, Vuilleumier N., Burger F, Roversi G., Tamborino C., Casetta I., Seraceni S., Trentini A., Padroni M., Dallegri F Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. Eur J Clin Invest. 2015; 45 (6): 579-86. doi: 10.1111/eci.12446.
- Ganz P., Amarenco P., Goldstein L.B., Sillesen H., Bao W., Preston G.M., Welch K.M.A. SPARCL Steering Committee. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017; 48 (12): 3223-31. DOI: 10.1161/ STROKEAHA.117.017965.
- Zou C., Pei S., Yan W., Lu Q., Zhong X., Chen Q., Pan S., Wang Z., Wang H., Zheng D. Cerebrospinal Fluid Osteopontin and Inflammation-Associated Cytokines in Patients With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Front Neurol. 2020; 11: 519692. doi: 10.3389/fneur.2020.519692.
- Rentsendorj A., Sheyn J., Fuchs D.T., Daley D., Salumbides B.C., Schubloom H.E., Hart N.J., Li S., Hayden E.Y., Teplow D.B., Black K.L., Koronyo Y., Koronyo-Hamaoui M. A novel role for osteopontin in macrophage-mediated amyloid-β clearance in Alzheimer's models. Brain Behav Immun. 2018; 67: 163-80. doi: 10.1016/j.bbi.2017.08.019.
Supplementary files
![](/img/style/loading.gif)